In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist Pharmaceuticals, Inc.

http://www.cubist.com

Latest From Cubist Pharmaceuticals, Inc.

A Dramatically Changing Landscape In Acute Myeloid Leukemia

Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.

Market Intelligence Cancer

Fixed Combinations Of ‘Old Antibiotic’ Plus New Moiety Eligible For NCE Exclusivity, US FDA Says

A 2008 law that limited exclusivity for certain antibiotics to three years does not apply to Allergan’s Avycaz, which combines an approved old antibiotic active moiety and a new active moiety, CDER exclusivity board concludes.

Intellectual Property Legal Issues

Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors

Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round. 

Financing Innovation

Korea To Toughen Co-Bioequivalence Study System

Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.

Legislation Generic Drugs
See All

Company Information

  • Industry
  • Biotechnology
  • Other Names / Subsidiaries
    • Adolor Corporation (ADLR)
    • Calixa Therapeutics, Inc.
    • Optimer Pharmaceuticals, Inc.
    • Trius Therapeutics, Inc.
UsernamePublicRestriction

Register